TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02578472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule\*20 mg) in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule\*20 mg) in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule\*20 mg) in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule\*20 mg) in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule\*20 mg) in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule\*20 mg) in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo will be administered orally.
Study: NCT00971633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment A (Zofran, ondansetron)
Description: an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment A (Zofran, ondansetron)
Description: an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment A (Zofran, ondansetron)
Description: an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment A (Zofran, ondansetron)
Description: an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment A (Zofran, ondansetron)
Description: an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment A (Zofran, ondansetron)
Description: an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment B (Zofran, ondansetron)
Description: a single 8 mg tablet of Zofran marketed in the U.K., taken PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment B (Zofran, ondansetron)
Description: a single 8 mg tablet of Zofran marketed in the U.K., taken PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment B (Zofran, ondansetron)
Description: a single 8 mg tablet of Zofran marketed in the U.K., taken PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment B (Zofran, ondansetron)
Description: a single 8 mg tablet of Zofran marketed in the U.K., taken PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment B (Zofran, ondansetron)
Description: a single 8 mg tablet of Zofran marketed in the U.K., taken PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment B (Zofran, ondansetron)
Description: a single 8 mg tablet of Zofran marketed in the U.K., taken PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment C (Zofran, ondansetron)
Description: a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment C (Zofran, ondansetron)
Description: a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO
Study: NCT04590222

Intervention type: OTHER
Intervention: blood sample
Description: One blood sample of 60 mL (EDTA)

Intervention type: OTHER
Intervention: blood sample
Description: One blood sample of 60 mL (EDTA)
Study: NCT01343420

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dog Hair Extract, ALK-Abelló, Inc.
Description: ALK-Abelló dog epithelial 1:10w/v glycerin
Study: NCT04545060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VIR-7831 (sotrovimab)
Description: VIR-7831 (sotrovimab) given by intravenous infusion (single dose)
Study: NCT02089763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegylated recombinant human arginase
Study: NCT03844152

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented whey concentrate
Description: The investigated dietary supplement is a form of lacto-fermented whey concentrate (FWC), which has been deproteinised and then diluted (1/20) in sugar-free flavoured water to improve palatability. The main solute within the lacto-fermented whey is L-(+)-lactic acid (7%), produced through bacterial fermentation of the milk sugar lactose. The research team will provide non-descriptive bottles of drink to all volunteers. The flavour of the FWC will be masked by the flavoured water. In order to assess compliance and minimize an initial treatment effect, a 14 day run-in period during which only flavoured water is to be consumed will be completed by all volunteers. At the same time, this period will act as a wash-out, as volunteers will be asked to abstain from the use of any dietary supplements during this period and the rest of the study. The daily energy content of the FWC is 4kcal.
Study: NCT03348722

Intervention type: OTHER
Intervention: Active surveillance
Description: PSA testing (every 3 months, then every 6 after 30 months), clinical visit and DRE every 6 months, prostate biopsy after 1, 4 and 7 years

Intervention type: PROCEDURE
Intervention: Radical prostatectomy
Description: Radical prostatectomy (open, laparoscopic or robotic)

Intervention type: RADIATION
Intervention: Radiotherapy
Description: External radical radiotherapy or brachitherapy

Intervention type: PROCEDURE
Intervention: Other radical treatments
Description: High intensity focal ultrasound, cryotherapy, others
Study: NCT03594500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PockeTalker
Description: The intervention group will receive PockeTalkers (hearing assistance devices) while they receive care in the ED
Study: NCT00971633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment C (Zofran, ondansetron)
Description: a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment C (Zofran, ondansetron)
Description: a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment C (Zofran, ondansetron)
Description: a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Treatment C (Zofran, ondansetron)
Description: a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO
Study: NCT01400074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib, Imatinib
Description: Nilotinib: 400 mg twice daily Imatinib: 400 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib, Imatinib
Description: Nilotinib: 400 mg twice daily Imatinib: 400 mg twice daily
Study: NCT03753815

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 19G FNA needle
Description: Puncture of AIP under Endoscopic Ultrasonography, with a 19-gauge FNA needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 20G FNB needle
Description: Puncture of AIP under Endoscopic Ultrasonography, with a 20-gauge FNB needle
Study: NCT03942146

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information on smoking cessation
Description: Smoking cessation is recommended 6 weeks before and after surgery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information on smoking cessation
Description: Smoking cessation is recommended 6 weeks before and after surgery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information on smoking cessation
Description: Smoking cessation is recommended 6 weeks before and after surgery
Study: NCT02738762

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glutamine supplementation
Description: glutamine supplementation guided by glutamine levels in plasma
Study: NCT04606368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermage FLX
Description: Monopolar radiofrequency will be applied through the Thermage FLX machine to the subject's right lower jaw and submentum area.
Study: NCT06318221

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental (Immunonutrition) Group
Description: Immunonutrition was given to the patients in the intervention group and ready-to-use liquid in addition to their normal nutrition 5 days before the operation. The patients were instructed to consume three enteral products per day as taken between meals.~In the postoperative period, feeding was started in the first 24 hours with the NG tube placed during the operation. The ready-to-use immunonutrition product was given to the patients in the intervention group.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator Group ( Standard enteral nutrition)
Description: Standard enteral nutrition was given to patients in the control group in addition to their normal nutrition 5 days before the operation. The patients were instructed to consume three enteral products per day between meals.~In the postoperative period, feeding was started in the first 24 hours with the NG tube placed during the operation. Liquid standard enteral nutrition was given to the patients in the control group.
Study: NCT04436588

Intervention type: GENETIC
Intervention: Epigenetic signatures
Description: Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
Study: NCT00055848

Intervention type: GENETIC
Intervention: cytogenetic analysis

Intervention type: GENETIC
Intervention: gene mapping

Intervention type: GENETIC
Intervention: microarray analysis
Study: NCT04021316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dCELL® Human Dermis (decellularised dermal skin allograft - DCD)
Description: DCD is produced from split thickness skin grafts (which comprise the epidermis and upper part of the dermis), and is retrieved from deceased tissue donors. All epidermal and cellular components from the dermis are removed in a patented sequential decellularisation process. As a decellularised graft, dCELL® Human Dermis fully integrates into the wound bed after application, replacing lost dermal tissue. It provides a scaffold into which the recipient's cells can grow, becoming vascularised and supporting the generation of a new epidermis, ultimately regenerating into normal skin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression bandaging therapy
Description: Compression therapy will be according to local practice and may include multilayer elastic compression bandaging or stockings delivering 20 to 40mm/Hg pressure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression bandaging therapy
Description: Compression therapy will be according to local practice and may include multilayer elastic compression bandaging or stockings delivering 20 to 40mm/Hg pressure.
Study: NCT03855241

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational Sheet
Description: The informational sheet details how use opioid medicines safely, and lists ways to properly dispose of leftover opioids

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational Sheet
Description: The informational sheet details how use opioid medicines safely, and lists ways to properly dispose of leftover opioids
Study: NCT03594500

Intervention type: OTHER
Group type: OTHER
Intervention: No PockeTalker
Description: The control group will not receive PockeTalkers while they receive care in the ED
Study: NCT03855241

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DisposeRx Drug Disposal kit
Description: DisposeRx is a powder that is activated with water and traps leftover drugs (i.e. pills, capsules, caplets, liquids or tablets) in a semi-solid gel. The trapped drug cannot be retrieved from the resulting gel material for misuse, abuse or to leach into landfills. The participant can then throw away the biodegradable solid material in the prescription bottle into the trash, as it is safe for the environment.
Study: NCT03024385

Intervention type: BEHAVIORAL
Intervention: Well Child Visits
Description: Mothers of young infants will be screened for maternal behaviors that affect the outcome of future pregnancies. These behaviors are related to the following: family planning; smoking status, prenatal vitamin use and maternal depression. Mothers with positive screens will be offered appropriate resources. This will all take place during the child's routine well-child visit.
Study: NCT03688945

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: Attend art viewing sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04935970

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnostic blood test
Description: vitamin D deficiency/insufficiency reveal, hyperhomocysteinaemia reveal

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnostic blood test
Description: vitamin D deficiency/insufficiency reveal, hyperhomocysteinaemia reveal
Study: NCT02771886

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surf the Urge
Description: The intervention teaches clients to be aware of and accept their feelings, thoughts, and sensations in a non-judgmental manner. Clients learn to remain present within the moment, become aware of their urges, and focus on accepting thoughts and feelings rather than suppressing or changing them. It utilizes visual imagery to assist clients in utilizing more acceptance skills; the client imagines his urges as waves within the ocean and then imagines surfing the waves.~Some interventionists also provide psychoeducation. Clients learn that urges will not last forever; clients are also taught information about reinforcing urges. The interventionist explains that if clients do not reinforce urges (e.g., do not smoke when an urge to smoke arises) they will eventual subside; however, reinforcing urges (smoke when an urge to smoke arises) will produce stronger urges. Emphasis is placed on the belief that clients have the choice to refrain from engaging in urge-related behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surf the Urge
Description: The intervention teaches clients to be aware of and accept their feelings, thoughts, and sensations in a non-judgmental manner. Clients learn to remain present within the moment, become aware of their urges, and focus on accepting thoughts and feelings rather than suppressing or changing them. It utilizes visual imagery to assist clients in utilizing more acceptance skills; the client imagines his urges as waves within the ocean and then imagines surfing the waves.~Some interventionists also provide psychoeducation. Clients learn that urges will not last forever; clients are also taught information about reinforcing urges. The interventionist explains that if clients do not reinforce urges (e.g., do not smoke when an urge to smoke arises) they will eventual subside; however, reinforcing urges (smoke when an urge to smoke arises) will produce stronger urges. Emphasis is placed on the belief that clients have the choice to refrain from engaging in urge-related behaviors.
Study: NCT01656538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study: NCT00686855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus elixir taken as an oral rinse four times a day for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone elixir taken as an oral rinse 4 times a day for 4 weeks
Study: NCT04481074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training will be performed using the tapered flow-resistive loading trainer (POWERbreathe®).
Study: NCT03260010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Description: Infectofos 5 g
Study: NCT01656538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reolysin
Study: NCT04967963

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAM
Description: Transplantation of HAM
Study: NCT01104909

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical
Description: Each patient will be submitted a clinical evaluation, considering signals of overload.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrical bioimpedance
Description: From electrical bioimpedance data, will be fixed a revised dry weight for each patient.
Study: NCT02853370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine and Rituximab
Study: NCT04333238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New progress note template
Description: Residents assigned to document with new progress note template

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard progress note template
Description: Residents assigned to document with standard progress note template
Study: NCT02912585

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of own mother's colostrum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oropharyngeal administration of sterile water (placebo)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oropharyngeal administration of donor human milk
Study: NCT03300544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo chemoradiation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Given intralesionally
Study: NCT03801889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-420
Description: Self-administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-420
Description: Self-administered by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-420
Description: Self-administered by mouth
Study: NCT02148289

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate rich beverage
Description: Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
Study: NCT04935970

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnostic blood test
Description: vitamin D deficiency/insufficiency reveal, hyperhomocysteinaemia reveal

Intervention type: DIAGNOSTIC_TEST
Intervention: neuropsychological test
Description: neuropsychological test, including tas-26 scale, Beck's Depression Inventory, Spielberg-Hanin'scale.
Study: NCT02148289

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate free beverage
Description: Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
Study: NCT04244123

Intervention type: COMBINATION_PRODUCT
Intervention: integrated information and nurse led telephone clinic
Description: combining web-based information from easypod connect with nurse led telephone clinic

Intervention type: COMBINATION_PRODUCT
Intervention: integrated information and nurse led telephone clinic
Description: combining web-based information from easypod connect with nurse led telephone clinic

Intervention type: COMBINATION_PRODUCT
Intervention: integrated information and nurse led telephone clinic
Description: combining web-based information from easypod connect with nurse led telephone clinic

Intervention type: COMBINATION_PRODUCT
Intervention: integrated information and nurse led telephone clinic
Description: combining web-based information from easypod connect with nurse led telephone clinic

Intervention type: COMBINATION_PRODUCT
Intervention: integrated information and nurse led telephone clinic
Description: combining web-based information from easypod connect with nurse led telephone clinic
Study: NCT01049711

Intervention type: DRUG
Intervention: erythropoietin
Study: NCT00369655

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Study: NCT01524679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a plus nucleos(t)ide(s)
Description: Pegylated interferon alfa-2a, s.c. 180 μg 1x/wk in addition to nucleos(t)ide(s)